Comparing a Novel Anti-BCMA NanoCAR with a Conventional ScFv-Based CAR for the Treatment of Multiple Myeloma

Multiple myeloma (MM) is an incurable hematologic malignancy arising from clonal plasma cells, with poor long-term outcomes due to inevitable relapse after conventional therapies. Chimeric antigen receptor (CAR) T-cell immunotherapy targeting B-cell maturation antigen (BCMA) has shown remarkable eff...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Mégane Jassin, Chloé Onkelinx, Valentina Bocuzzi, Bianca E Silva, Oswin Kwan, Alix Block, Sophie Dubois, Coline Daulne, Guillaume Marcion, Sandra Ormenese, Emmanuel Di Valentin, Frédéric Baron, Céline Grégoire, Grégory Ehx, Tham Thi Nguyen, Jo Caers
Format:	Artigo
Jezik:	Inglês
Izdano:	MDPI AG 2025-12-01
Serija:	Cells
Teme:	MM BCMA nanobody CAR-T cells immunotherapy
Online dostop:	https://www.mdpi.com/2073-4409/14/24/1944
Oznake:	Označite Brez oznak, prvi označite!